| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nintedanib |
| Brand | Ofev® |
| Indication | Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). |
| Assessment Process | |
| Rapid review commissioned | 30/01/2015 |
| Rapid review completed | 18/02/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 10/09/2015 |
| NCPE assessment completed | 22/02/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations June 2017.
